Gilead Sciences is a publicly traded company in the Healthcare sector. This company operates across Healthcare and is subject to various Congressional legislative and regulatory actions. HillSignal is tracking 3 active Congressional signals mentioning Gilead Sciences, including 3 bills. The current legislative sentiment is predominantly bullish, suggesting potential tailwinds from government policy.
The PrEP and PEP are Prevention Act (HR5127) mandates zero-cost coverage of HIV prevention drugs and associated lab monitoring across all US insurance programs. This early-stage bipartisan bill creates direct volume upside for Gilead ($GILD) on branded PrEP, Viatris ($VTRS) on generic PrEP, and Labcorp ($LH) on mandatory diagnostic services. Merck ($MRK) is excluded from the causal chain because its islatravir candidate is not FDA-approved and the bill only covers approved drugs.
HR1492 retroactively extends the Medicare price negotiation safe harbor for small-molecule drugs from 7 to 11 years, matching biologics. This shields billions in revenue for major pharma companies, particularly pure-play small-molecule firms like Vertex and large players with top-selling Part D drugs like Pfizer, Bristol-Myers Squibb, and Gilead. The bill is early-stage with 67 cosponsors and a Republican sponsor, giving it moderate momentum.
HR7385 is an early-stage bill authorizing up to $10M per grant for PrEP programs, with no specified total funding or direct corporate beneficiaries. It has been referred to committee with 14 cosponsors, all Democrats. At this procedural stage, the bill has no measurable market impact.